

27 March 2024

Urothelial and Endometrial Cancer Treatments

Q1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Please note these figures are taken from bladder tumour site.

Atezolizumab (Tecentriq)		<5
Avelumab (Bavencio)		<5
Carboplatin single agent or in any other combination		<5
Carboplatin with Gemcitabine		<5
Carboplatin with Paclitaxel		<5
Cisplatin single agent or in any other combination		<5
Cisplatin with Gemcitabine		<5
Nivolumab (Opdivo)		<5
Pembrolizumab (Keytruda)		<5
Other active systemic anti-cancer therapy	Gemcitabine & Cisplatin	<5
	Gemcitabine & Carboplatin	<5
	Avelumab	<5
	Cisplatin & Etoposide	<5
	Paclitaxel	<5
	Carboplatin & Etoposide	<5
Palliative care only	Not available on RISOH	

Q2. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

We do.

Q3. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

Dostarlimab (Jemperli)		<5
Hormone therapy (Progesterone or Letrozole)		<5
Pembrolizumab (Keytruda) monotherapy		<5
Pembrolizumab + Lenvatinib (Keytruda + Lenvima)		<5

27 March 2024

Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	Carboplatin AUC6	21
	Cisplatin	<5
	Paclitaxel & Carboplatin	16
	Weekly Carboplatin AUC1.5	<5
Any other SACT	Lenvatinib/Pembrolizumab	<5
	Paclitaxel	6

Q4. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

Not available on RISOH.

Where numbers are low, we have used <5 rather than release the exact figure. This is because doing so has the potential to make those people identifiable, and so those figures are exempt from release under Section 40(2) of the FOI Act which relates to personal Information relating to a third party.